See more : The Siam Cement Public Company Limited (TCM1.F) Income Statement Analysis – Financial Results
Complete financial analysis of Revvity, Inc. (0KHE.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Revvity, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Yip’s Chemical Holdings Limited (YIPCF) Income Statement Analysis – Financial Results
- InterPrivate II Acquisition Corp. (IPVA-UN) Income Statement Analysis – Financial Results
- Zodiac Energy Limited (ZODIAC.BO) Income Statement Analysis – Financial Results
- Larsen & Toubro Limited (LTOD.L) Income Statement Analysis – Financial Results
- Daihatsu Diesel Mfg. Co., Ltd. (6023.T) Income Statement Analysis – Financial Results
Revvity, Inc. (0KHE.L)
About Revvity, Inc.
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 2.75B | 3.31B | 3.83B | 3.78B | 2.88B | 2.78B | 2.26B | 2.12B | 2.10B | 2.07B | 2.16B | 2.11B |
Cost of Revenue | 1.21B | 1.55B | 1.55B | 1.79B | 1.59B | 1.53B | 1.23B | 1.14B | 1.13B | 1.13B | 1.18B | 1.14B |
Gross Profit | 1.54B | 1.76B | 2.28B | 1.99B | 1.29B | 1.25B | 1.03B | 972.25M | 971.51M | 937.02M | 976.35M | 966.74M |
Gross Profit Ratio | 55.98% | 53.16% | 59.62% | 52.62% | 44.84% | 45.04% | 45.61% | 45.96% | 46.16% | 45.27% | 45.25% | 45.92% |
Research & Development | 216.58M | 221.62M | 200.34M | 205.39M | 189.34M | 186.10M | 139.16M | 123.78M | 112.54M | 108.06M | 132.40M | 131.84M |
General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 941.63M | 757.99M | 741.61M | 765.33M | 698.24M | 694.17M | 585.56M | 542.80M | 585.70M | 647.87M | 580.85M | 627.92M |
Other Expenses | 80.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 1.24B | 979.61M | 941.95M | 970.72M | 887.57M | 880.27M | 724.72M | 666.58M | 725.38M | 777.55M | 763.39M | 866.54M |
Cost & Expenses | 2.45B | 2.53B | 2.49B | 2.76B | 2.48B | 2.41B | 1.95B | 1.81B | 1.86B | 1.91B | 1.94B | 2.00B |
Interest Income | 72.13M | 3.59M | 2.24M | 1.01M | 1.50M | 65.83M | 41.37M | 40.83M | 37.32M | 35.60M | 49.27M | 45.04M |
Interest Expense | 98.81M | 103.96M | 102.13M | 49.71M | 63.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 431.77M | 427.00M | 311.44M | 246.51M | 214.03M | 180.59M | 105.00M | 99.97M | 105.36M | 110.47M | 126.88M | 125.13M |
EBITDA | 813.25M | 1.30B | 1.62B | 1.20B | 609.55M | 518.76M | 424.63M | 405.96M | 352.17M | 291.56M | 331.73M | 223.24M |
EBITDA Ratio | 29.57% | 36.48% | 43.14% | 33.48% | 21.48% | 19.85% | 18.15% | 19.17% | 17.99% | 14.09% | 18.07% | 15.78% |
Operating Income | 300.56M | 781.12M | 1.34B | 1.02B | 405.48M | 370.97M | 304.63M | 305.67M | 273.27M | 181.10M | 263.09M | 206.99M |
Operating Income Ratio | 10.93% | 23.59% | 35.01% | 26.96% | 14.06% | 13.35% | 13.50% | 14.45% | 12.98% | 8.75% | 12.19% | 9.83% |
Total Other Income/Expenses | -117.59M | -129.29M | -136.42M | -113.43M | -168.34M | -113.29M | -7.92M | -50.51M | -64.46M | -57.23M | -99.41M | -151.83M |
Income Before Tax | 182.98M | 651.84M | 1.20B | 906.36M | 237.14M | 257.68M | 296.72M | 244.07M | 208.81M | 123.87M | 163.68M | 55.16M |
Income Before Tax Ratio | 6.65% | 19.68% | 31.44% | 23.96% | 8.22% | 9.28% | 13.15% | 11.54% | 9.92% | 5.98% | 7.59% | 2.62% |
Income Tax Expense | 3.47M | 139.16M | 314.15M | 178.27M | 9.39M | 20.21M | 139.83M | 28.36M | 20.02M | 6.27M | 10.58M | 16.13M |
Net Income | 693.09M | 569.18M | 943.16M | 728.10M | 227.56M | 238.79M | 113.02M | 233.68M | 188.79M | 130.14M | 174.27M | 71.29M |
Net Income Ratio | 25.20% | 17.19% | 24.64% | 19.25% | 7.89% | 8.60% | 5.01% | 11.05% | 8.97% | 6.29% | 8.08% | 3.39% |
EPS | 0.37 | 4.51 | 8.12 | 6.53 | 2.05 | 2.16 | 1.03 | 2.13 | 1.67 | 1.14 | 1.54 | 0.62 |
EPS Diluted | 1.44 | 4.50 | 8.08 | 6.49 | 2.04 | 2.14 | 1.02 | 2.12 | 1.67 | 1.14 | 1.54 | 0.62 |
Weighted Avg Shares Out | 481.51M | 126.16M | 116.17M | 111.51M | 110.83M | 110.56M | 109.86M | 109.48M | 113.04M | 114.16M | 113.16M | 114.98M |
Weighted Avg Shares Out (Dil) | 124.81M | 126.43M | 116.67M | 112.09M | 111.50M | 111.53M | 110.86M | 110.31M | 113.32M | 113.74M | 113.50M | 114.86M |
Source: https://incomestatements.info
Category: Stock Reports